Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699507 | 0.90 | FBP1 (0.38) | CNR1CNR2 | |
| SCHEMBL13092333 | 0.90 | AMY1A (0.37) | CMA1ERO1ASCN9ACYP3A4CYP3A5 | |
| SCHEMBL4219230 | 0.84 | FBP1 (0.39) | CYP3A4CNR1CNR2 | |
| SCHEMBL3711852 | 0.84 | FBP1 (0.39) | CYP3A4CNR1CNR2 | |
| SCHEMBL275083 | 0.82 | CYP3A4 (0.37) | ERO1ASCN9ACYP3A4CYP3A5CNR1 | |
| SCHEMBL279502 | 0.82 | CYP3A4 (0.37) | ERO1ASCN9ACYP3A4CYP3A5CNR1 | |
| SCHEMBL275084 | 0.82 | CYP3A4 (0.37) | ERO1ASCN9ACYP3A4CYP3A5CNR1 | |
| SCHEMBL7839339 | 0.81 | FBP1 (0.46) | CYP3A4CNR1 | |
| SCHEMBL1740283 | 0.81 | CMA1 (0.33) | CMA1ERO1A | |
| SCHEMBL3710224 | 0.81 | GABRA1 (0.32) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421866-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2010121995-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | SIK3, RB1, CCND3 | CMA1 4441/4885ERO1A 1887/4885SCN9A 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.